Caris Life Sciences (CAI) Amortization of Deferred Charges (2024 - 2026)

Caris Life Sciences' Amortization of Deferred Charges history runs 3 years deep, the most recent figure standing at $1.3 million for Q1 2026.

• On a quarterly basis, Amortization of Deferred Charges fell 8.88% year-over-year to $1.3 million in Q1 2026; TTM through Mar 2026 was $5.5 million, a N/A change from a year earlier, with the FY2025 full-year figure at $5.6 million, changed 0.29% from the prior year.
• Amortization of Deferred Charges advanced to $1.3 million in Q1 2026 per CAI's latest filing, from $1.3 million in the prior quarter.
• Across five years, Amortization of Deferred Charges topped out at $1.5 million in Q2 2025 and bottomed at $1.3 million in Q4 2025.
• The 3-year median for Amortization of Deferred Charges is $1.4 million (2024), against an average of $1.4 million.
• Across the five-year window, Amortization of Deferred Charges rose 3.82% in 2025 and declined 8.88% in 2026, its largest moves.
• Year by year, Amortization of Deferred Charges stood at $1.4 million in 2024, then decreased by 8.35% to $1.3 million in 2025, then rose by 4.83% to $1.3 million in 2026.
• Per Business Quant, the three latest CAI Amortization of Deferred Charges figures stand at $1.3 million (Q1 2026), $1.3 million (Q4 2025), and $1.4 million (Q3 2025).